Last reviewed · How we verify

NCT04429815: MAGIC

Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19

Completed Last updated 17 August 2021
What this trial tests

trial testing Serological test for COVID-19. in Smoking Behaviors in 195 participants. Completed in 26 May 2021.

Timeline
25 August 2020
Primary endpoint
26 May 2021
26 May 2021

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusCompleted
Study typeOBSERVATIONAL
Enrollment195
Start date25 August 2020
Primary completion26 May 2021
Estimated completion26 May 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Smoking Behaviors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Several studies have shown that smokers have a higher risk of developing a severe form of COVID-19 once a person has been infected. This is explained by the damage caused by smoking at the bronchopulmonary level and an overexpression of some coronavirus receptors at the pulmonary level when exposed to tobacco. In contrast, recent data indicate that smokers are proportionally less infected with the COVID-19 virus since all available cohort data from around the world show a very low rate of smokers among COVID-19 infected subjects. The mechanisms at the origin of this protective effect are not known. All of these data lead us to question the real role of nicotine in the protective effect of tobacco observed in the general population against infection by the COVID-19 virus. The objectives are : * To show that subjects taking nicotine substitutes as part of a smoking cessation program are less infected with COVID-19 than non-smokers. * To show that active smokers are less infected with COVID-19 than non-smokers. * To compare the percentage of positive serological tests in subjects taking nicotine substitutes to the percentage of positive serological tests in active smokers.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors.
    Oliveira ASF, Oliveira ASF, Ibarra AA, Bermudez I, et al · · 2021 · cited 47× · PMID 33609494 · DOI 10.1016/j.bpj.2021.01.037
  2. Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers.
    Voinsky I, Gurwitz D. · · 2020 · cited 26× · PMID 32757420 · DOI 10.1002/ddr.21729
  3. <i>In silico</i> Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor.
    Mohammadi S, Heidarizadeh M, Entesari M, Esmailpour A, et al · · 2020 · cited 21× · PMID 33080900 · DOI 10.3390/microorganisms8101600
  4. Role of Cigarette Smoke on Angiotensin-Converting Enzyme-2 Protein Membrane Expression in Bronchial Epithelial Cells Using an Air-Liquid Interface Model.
    Caruso M, Distefano A, Emma R, Di Rosa M, et al · · 2021 · cited 15× · PMID 33859566 · DOI 10.3389/fphar.2021.652102
  5. Psychotropics and COVID-19: An analysis of safety and prophylaxis.
    Javelot H, Straczek C, Meyer G, Gitahy Falcao Faria C, et al · · 2021 · cited 3× · PMID 34548153 · DOI 10.1016/j.encep.2021.08.002
  6. Determination of soluble angiotensin-converting enzyme 2 in saliva samples and its association with nicotine.
    Bru S, González-Marrón A, Lidón-Moyano C, Carballar R, et al · · 2023 · PMID 36195157 · DOI 10.1016/j.envres.2022.114443
  7. Harnessing the Sars-cov-2 Spike Protein Binding Affinity to Ace2 Receptor Through Narcotinic Compounds Combined With Adjuvants: an in Silico Insight
    Mohammadi S, Doustkhah E, Sakhaee N, Esmailpour A, et al · · 2021 · DOI 10.21203/rs.3.rs-254891/v1
  8. Blocking SARS-CoV-2 Spike Protein binding to ACE2 receptor through Narcotinic Compounds Combined with Adjuvants: an in silico Insight
    Mohammadi S, Esmailpour A, Sakhaee N, Doustkhah E. · · 2021 · DOI 10.21203/rs.3.rs-205356/v1

Verify or expand the search:

Other recruiting trials for Smoking Behaviors

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04429815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing